Concurrent with Iwicki's departure, the Board appointed Todd Bazemore as the interim CEO and principal executive officer. Bazemore, 54, has been with Kala Bio since November 2017, previously ...

The startup biotech Kala Pharmaceuticals has taken another step forward in its journey to the clinic. The Waltham, MA-based developer of mucus-penetrating particle treatments--one of Robert Langer ...